Full Press Release Details
Lexaria Operations Update
Kelowna, BC / March 8, 2016 / Lexaria, Corp. (OTCQB:LXRP)
(CSE:LXX) (the Company ) provides an update on operations.
The centerpiece of Lexaria s uniqueness is its patent pending
technology that enables higher rates of absorption of certain molecules such as
vitamins and cannabinoids while simultaneously masking and at times even
eliminating inherent strong flavours and/or odors typical of those molecules.
The family of Lexaria Energy and ViPovaTM products have demonstrated
to thousands of satisfied consumers the overwhelming effectiveness of this
Lexaria remains committed to its consumer products but also
points out that the products serve as an effective showcase of the excellent
taste experiences possible with the remarkable technology. As such, the Company
has always believed that opportunities to license the technology to others can
build revenue streams unrelated to the sale of Lexaria or ViPovaTM
Having completed the first of several applicability tests with
potential partners, Lexaria is now in discussions, some advanced and others
preliminary, regarding licensing its technology for the purposes of enabling
specialty food manufacturers to offer improved food consuming experiences.
Although no final agreements have yet been reached, the increase in interested
potential licensees in recent weeks is notable.
Within the protein bar category, over 300 people enjoyed the
Lexaria Protein Bars at the recent California Cannabis Business Expo located in
San Francisco to wildly positive reviews. As well, recipe development continues
to improve the bars with several improved recipe combinations currently being
explored for potential release this year.
Meanwhile, after working with Lexaria in different capacities
over the past nine years, Mr. Tom Ihrke has resigned from Lexaria and from
Poviva LLC to pursue other opportunities. Tom is a beloved member of the Lexaria
community and we wish him well in all his endeavours.
Finally, Lexaria reminds all shareholders of the upcoming
Annual General Meeting to be held March 23, 2016, and encourages all who are
eligible to cast their votes.
Lexaria is a food sciences company focused on
the delivery of active compounds that can behave as superfoods through its
proprietary infusion technologies. Lexaria s technology enables higher
bioavailability rates for CBD; THC; NSAIDs; Nicotine and other molecules than is
possible without lipophilic enhancement technology. This can allow for lower
overall dosing requirements and/or higher effectiveness in active molecule
delivery. Lexaria hopes to reduce other common but less healthy ingestion
methods such as smoking as it embraces the benefits of public health.
legal hemp oil extracts, grown from agricultural hemp in locations where it is
legal to do so, in ViPovaTM-branded tea, coffee, and hot chocolate.
ViPovaTM uses its patent-pending process to infuse concentrated
amounts of hemp oil within lipids, providing more bioactivity and comfort to the
body during the absorption process. Only ViPovaTM has this
ground-breaking technology for hemp oil/lipid infusion. www.vipova.com
FOR FURTHER INFORMATION PLEASE CONTACT:
FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements. Statements
which are not historical facts are forward-looking statements. The Company makes
forward-looking public statements concerning its expected future financial
position, results of operations, cash flows, financing plans, business strategy,
products and services, competitive positions, growth opportunities, plans and
objectives of management for future operations, including statements that
include words such as "anticipate," "if," "believe," "plan," "estimate,"
"expect," "intend," "may," "could," "should," "will," and other similar
expressions are forward-looking statements, including but not limited to: that
the Company s technology enables higher rates of absorption of certain molecules
such as vitamins and cannabinoids while simultaneously masking and at times even
eliminating inherent strong flavors and/or odors typical of those molecules, or
that the technology will function in a similar manner if tested with THC,
nicotine, or any of the other molecules named in our patent applications. Such
forward-looking statements are estimates reflecting the Company's best judgment
based upon current information and involve a number of risks and uncertainties,
and there can be no assurance that other factors will not affect the accuracy of
such forward-looking statements. Access to capital, or lack thereof, is a major
risk and there is no assurance that the Company will be able to raise required
working capital. Factors which could cause actual results to differ materially
from those estimated by the Company include, but are not limited to, government
regulation, managing and maintaining growth, the effect of adverse publicity,
litigation, competition, the patent application and approval process and other
factors which may be identified from time to time in the Company's public
announcements and filings. There is no assurance that the hemp oil sector, or
alternative health businesses will provide any benefit to Lexaria, or that the
Company will experience any growth through participation in these sectors. There
is no assurance that existing capital is sufficient for the Company's needs or
that it will be able to raise additional capital. There is no assurance that any
planned corporate activity, business venture, or initiative will be pursued, or
if pursued, will be successful. There is no assurance that any hemp oil or
cannabinoid-based product will promote, assist, or maintain any beneficial human
health conditions whatsoever. There is no assurance that any patent application
in the USA or any other nation or under any treaty will result in the award of
an actual patent; nor that an award of any actual patent will protect against
challenges from unknown third parties. There is no assurance that any of
Lexaria s postulated uses, benefits, or advantages for the patent-pending
technology will in fact be realized in any manner or in any part. No statement
herein has been evaluated by the Food and Drug Administration (FDA).
ViPovaTM products are not intended to diagnose, treat, cure or
prevent any disease.
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.